Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145041 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
A Phase 1 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00145041 is a Phase 1 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 7 participants.
The verdict
NCT00145041, a Phase 1 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics). This study will also assess the safety of VSLI and to see if VSLI will slow the growth or shrink tumors in patients with metastatic melanoma that has resulted in liver impairment, and who have relapsed after previous therapies.
Interventions
- DRUG Vincristine Sulfate Liposomes Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145041
The ClinicalTrials.gov registry entry for NCT00145041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vincristine Sulfate Liposomes Injection is the first listed.
NCT00145041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145041 about?
NCT00145041 is a clinical study titled "Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction". The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics). This study will also assess the safety of VSLI and to see if VSLI will slow the growth or shrink tum...
What is the current status of trial NCT00145041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2005-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00145041?
The interventions under investigation include: Vincristine Sulfate Liposomes Injection (DRUG).
Who is sponsoring clinical trial NCT00145041?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.